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Pancreatic β-cells, located within the 
islets of Langerhans, are key players in 
the control of blood glucose homeosta-
sis. The amount of insulin secreted by 
these cells is precisely adjusted to avoid 
hypo- or hyperglycaemic episodes and 
prevent the appearance of diabetes melli-
tus. Pregnancy and obesity are associated 
with diminished insulin sensitivity of tar-
get tissues and a consequent rise in insu-
lin needs. The increased insulin demand 
is normally compensated by expansion of 
β-cells and improvement in their secre-
tory activity.1 A better understanding 
of these adaptive events could open new 
therapeutic perspectives for prevention 
and/or treatment of type 2 and gestational 
diabetes. MicroRNAs are gene expression 
regulators that reduce translation and/or 
stability of target mRNAs by binding to 
their 3'-untranslated regions. These tiny 
RNA molecules govern different physi-
ological and pathological processes and 
participate to the regulation of β-cell 
functions.2 We recently provided evidence 
that microRNAs contribute to compensa-
tory β-cell mass expansion in response to 
insulin resistance associated with preg-
nancy and obesity.3
We found that in rat islets β-cell 
expansion during pregnancy is coupled to 
changes in the level of some microRNAs.3 
These changes were reproduced in dissoci-
ated rat islet cells by transfecting oligonu-
cleotides that either mimic or block each 
microRNA. This revealed that knock-
down of miR-338-3p, a microRNA down-
regulated in the islets of pregnant rats, 
does not interfere with the secretory prop-
erties of β-cells, but boosts their prolif-
eration and improves their survival under 
pro-apoptotic conditions. Interestingly, 
the level of miR-338-3p is also diminished 
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in the islets of animal models character-
ized by obesity, insulin resistance and 
compensatory β-cell mass expansion, the 
db/db mice and mice fed a high-fat diet. 
These observations point to a broader 
involvement of miR-338-3p in compensa-
tory β-cell mass expansion. The decrease 
of miR-338-3p observed in pregnancy and 
obesity can be reproduced by activating 
the cAMP/PKA-dependent pathway. Our 
data suggest that, during pregnancy, miR-
338-3p levels are controlled by the uncon-
ventional estradiol receptor GPR30 that is 
coupled to the cAMP signaling pathway. 
Indeed, estradiol levels increase during 
gestation and islet GPR30 expression is 
strongly upregulated concomitantly with 
β-cell mass expansion. Downregulation of 
miR-338-3p in obese mice is unlikely to be 
triggered by the same mechanism, because 
the expression of GPR30 is unchanged in 
the islets of these animals. An attractive 
candidate for the control of miR-338-3p 
expression in obese mice is glucagon-like 
peptide 1 (GLP1), a hormone that stimu-
lates β-cell proliferation and survival via a 
cAMP-dependent mechanism. Indeed, we 
showed that rat and human islets exposed 
to a GLP1 analog contain reduced levels 
of miR-338-3p. Moreover, previous stud-
ies reported increased GLP1 production 
in islets of type 2 diabetic donors and of 
obese animals.4,5
Our study raises a number of ques-
tions that remain unsolved so far. A point 
that deserves further investigations is the 
possible contribution of the miR-338-3p 
hosting gene to the control of the β-cell 
mass. Most microRNAs are generated 
from independent transcriptional units 
located outside protein-coding regions, 
but a fraction of them is excised from 
introns of protein-coding transcripts. This 
is the case of miR-338-3p, which is tran-
scribed from an intron of the gene cod-
ing for the apoptosis-associated tyrosine 
kinase (AATK). AATK family members 
are predominantly expressed in brains, 
where they induce cell death and neurite 
extension.6 At present, no information 
is available about the function of AATK 
in β-cells. The expression of AATK is 
downregulated by cAMP-raising agents 
and by exposure to estradiol and GLP1 
analogs (our unpublished observations). 
Moreover, we found that during gesta-
tion, the decrease in AATK levels in rat 
islets parallels that of miR-338-3p and 
coincides with the changes in β-cell mass. 
This may indicate a cooperative action of 
miR-338-3p and its hosting gene in the 
control of β-cell mass expansion under 
insulin resistance conditions.
In our study, following blockade of 
miR-338-3p, we detected differences in 
the expression of many genes involved in 
proliferation and apoptosis.3 However, 
the direct targets of miR-338-3p are still 
not identified. The tumor necrosis fac-
tor receptor II (TNFRII, also called 
TNFrsf1β) is predicted by computa-
tional programs to be a direct target 
of miR-338-3p. Indeed, modulation of 
miR-338-3p levels affects the expression 
of luciferase reporter constructs contain-
ing the 3'UTR sequence of TNFRII (our 
unpublished results). Moreover, we found 
that TNRFII is strongly upregulated in 
rat islets at day 14 of gestation. TNFRII 
occurs as a membrane-attached protein 
or in a soluble truncated form generated 
by proteolytic cleavage or by alternative 
splicing.7 Interestingly, serum levels of the 
soluble variant of TNFRII are higher in 
healthy than in type 2 diabetic subjects and 
correlate with insulin sensitivity.8 Among 
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missing and deserve further investiga-
tions. However, a better understanding 
of the molecular events controlled by this 
microRNA promises to open new perspec-
tives for the design of better pharmacolog-
ical treatments for type 2 and gestational 
diabetes.
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other effects, the reduction of islet miR-
338-3p expression occurring under con-
ditions of insulin resistance may possibly 
enable the production of larger amounts of 
the soluble form of TNFRII. This could 
potentially render β-cells more resistant 
to apoptosis favoring their compensa-
tory expansion. Indeed, overexpression 
of the soluble form of TNFRII protects a 
fibroblast cell line against TNFα-induced 
apoptosis,7 and other studies have identi-
fied TNFRII as a neuroprotective factor.9
Our study revealed a central role for 
microRNAs in compensatory β-cell mass 
expansion associated with pregnancy and 
obesity. Some important aspects of the 
mode of action of miR-338-3p are still 
Figure 1. Model explaining the regulation of mir-338-3p expression and its mode of action. under insulin resistance conditions associated with 
pregnancy and obesity, the augmented insulin needs are covered by an increase in the  β-cell mass and in hormone secretion. the rise in caMP levels 
resulting from occupation of GPr30 and GLP1 receptors leads to protein kinase a activation. this causes reduction of aatK gene transcription and 
decreased production of mir-338-3p that is generated from the seventh intron of the aatK mrNa. the presence of reduced amounts of mir-338-
3p promotes the expression of proliferative and/or anti-apoptotic genes, such as Birc5, Foxm1, cyclind2, igf1r, irs2, Bcl2 and Bcl-xl, and reduces the 
expression of the pro-apoptotic gene Bad. mir-338-3p will also directly inhibit tNFrii mrNa translation by binding to its 3'utr. Collectively, these 
events will result in β-cell proliferation and improved survival, permitting adaptive β-cell mass expansion to meet the increased insulin needs during 
pregnancy and obesity.
